Cure My Disease

Don't miss your cure!

 Log in / Sign up

New dosing strategy aims to reduce eye damage from myeloma drug

NCT ID NCT05847569

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 15, 2026 · Updated 4 times

Summary

This phase II trial is testing different doses and schedules of belantamab mafodotin, a drug that delivers chemotherapy directly to myeloma cells. The goal is to find a way to give the drug that causes fewer severe eye problems while still controlling the cancer. About 62 adults with multiple myeloma that has returned or stopped responding to other treatments will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
belantamab mafodotin (a targeted antibody-drug combination)
What this could lead to
If successful, this could lead to a safer dosing approach for belantamab mafodotin, reducing severe eye side effects while still controlling multiple myeloma.
What could go wrong
This is a small, early-phase trial (62 participants) testing different doses, not a cure. The drug may still cause side effects or not work well enough for broader use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT MULTIPLE MYELOMA REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

  • Mayo Clinic in Florida

    RECRUITING

    Jacksonville, Florida, 32224-9980, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.